Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: blankmind who wrote (7455)	4/25/1998 8:55:00 PM
From: Rashid Garuba	Read Replies (1) \| Respond to of 23519

The usual biased reporting. Negative Barron's articles that offer no new information have been bullish for the subject stock lately. Rashid

To: blankmind who wrote (7455)	4/26/1998 5:46:00 PM
From: NicholasC	Read Replies (1) \| Respond to of 23519

Blankmind, Barron's Online did state the following: <<But other potency drugs haven't given up the fight In the month that Viagra has been on the market, the Pfizer pill for treating male impotence has won 80% of new prescriptions for that condition. According to IMS America, a market-research firm, new prescriptions fell by more than 25% for alternative therapies, including Pharmacia & Upjohn's Caverject injection and Vivus's Muse, which a patient applies by squirting the medication up his urethra. But don't write off Viagra's rivals yet. "Anyone that has an effective drug therapy will have a niche," says Harin Padma-Nathan, a researcher and urologist in Santa Monica, California.>> I think that this is a positive for VVUS. -N